Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R)

Overview

Journal Subst Abuse

Publisher Sage Publications

Specialty Psychiatry

Date 2019 Apr 5

PMID 30944519

Citations 9

Authors

Stefan Christensen

Peter Buggisch

Stefan Mauss

Klaus Hw Boker

Tobias Muller

Hartwig Klinker

Tim Zimmermann

Yvonne Serfert

Bernd Weber

Jens Reimer

Heiner Wedemeyer

Affiliations

Soon will be listed here.

Abstract

Background: The importance of alcohol and cannabis consumption for the effectiveness of treatment of chronic hepatitis C virus (HCV) infection with direct acting antivirals (DAAs) in people on opioid substitution therapy (OST) has not been investigated in detail.

Methods: We investigated sustained virological response (SVR) rates and proportion of lost to follow-up (LTFU) between OST (n = 739) and non-OST patients (n = 7008) in the German Hepatitis C-Registry (Deutsches Hepatitis C-Register, DHC-R), which is a national multicenter prospective non-interventional real-world registry. Non-OST patients comprised patients with former/current drug use (non-OST/DU; n = 1500) and patients never consuming drugs (non-OST/NDU; n = 5508).

Findings: SVR 12/24 rates (intention to treat [ITT]) in patients consuming no or less than 30 g/day (women) or 40 g/day (men) were significantly higher in non-OST/NDU (range 91%-92%) vs OST patients (range 83%-86%), mainly due to significantly higher LTFU rates in OST (range 11%-12%) compared with non-OST/NDU (range 2%-3%). In non-OST/NDU with high alcohol consumption of more than 30/40 g/day, SVR 12/24 rates (ITT) were lower (85%) but did not differ to OST (85%) with high alcohol consumption. No significant differences could be seen for SVR 12/24 in per-protocol (PP) analysis independent of alcohol consumption or amount of alcohol intake. Cannabis use did not significantly influence SVR 12/24 in ITT or PP or LTFU.

Conclusions: High SVR rates could be achieved in both OST and non-OST patients irrespective of alcohol or cannabis consumption. However, LTFU is more likely in patients with current or former drug use than in patients without drug history and in patients with high alcohol consumption but occurred mainly after end of antiviral treatment (EOT), leaving a high chance for HCV elimination in these patients.

Citing Articles

HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12.

Milosevic I, Beronja B, Filipovic A, Mitrovic N, Simic J, Knezevic N Microorganisms. 2025; 12(12.

PMID: 39770757 PMC: 11677223. DOI: 10.3390/microorganisms12122554.

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.

Zarebska-Michaluk D, Brzdek M, Tronina O, Janocha-Litwin J, Sitko M, Piekarska A BMC Med. 2024; 22(1):486.

PMID: 39444018 PMC: 11515622. DOI: 10.1186/s12916-024-03699-z.

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.

Wedemeyer H, Di Marco V, Garcia-Retortillo M, Teti E, Fraser C, Morano Amado L Viruses. 2022; 14(11).

PMID: 36423102 PMC: 9695390. DOI: 10.3390/v14112493.

History of alcohol use does not predict HCV direct acting antiviral treatment outcomes.

Ia Okwor C, Petrosyan Y, Lee C, Cooper C J Assoc Med Microbiol Infect Dis Can. 2022; 7(3):233-241.

PMID: 36337601 PMC: 9629724. DOI: 10.3138/jammi-2021-0037.

Changes in alcohol use during hepatitis C treatment in persons who inject drugs.

Martin M, Roth P, Niu J, Pericot-Valverde I, Heo M, Padi A J Viral Hepat. 2022; 29(11):1004-1014.

PMID: 35997620 PMC: 9826277. DOI: 10.1111/jvh.13737.

References

Nelson P, Mathers B, Cowie B, Hagan H, Des Jarlais D, Horyniak D . Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378(9791):571-83. PMC: 3285467. DOI: 10.1016/S0140-6736(11)61097-0. View

Rengade C, Kahn J, Schwan R . Misuse of alcohol among methadone patients. Am J Addict. 2009; 18(2):162-6. DOI: 10.1080/10550490802544433. View

Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander L, Hickman M . Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(12):1385-1398. DOI: 10.1016/S1473-3099(16)30325-5. View

Scott N, Doyle J, Wilson D, Wade A, Howell J, Pedrana A . Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017; 47:107-116. DOI: 10.1016/j.drugpo.2017.07.006. View

Dore G, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O . Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016; 165(9):625-634. DOI: 10.7326/M16-0816. View

Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J . Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017; 47:202-208. DOI: 10.1016/j.drugpo.2017.05.025. View

Zielinski L, Bhatt M, Eisen R, Perera S, Bhatnagar N, MacKillop J . Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol. Syst Rev. 2016; 5(1):139. PMC: 4988054. DOI: 10.1186/s13643-016-0317-2. View

Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann O, Hansdottir I, Bjornsson E . Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018; 283(5):500-507. DOI: 10.1111/joim.12740. View

Hajarizadeh B, Cunningham E, Reid H, Law M, Dore G, Grebely J . Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018; 3(11):754-767. DOI: 10.1016/S2468-1253(18)30304-2. View

10.

Szabo G, Wands J, Eken A, Osna N, Weinman S, Machida K . Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res. 2010; 34(10):1675-86. PMC: 3253556. DOI: 10.1111/j.1530-0277.2010.01255.x. View

11.

Butner J, Gupta N, Fabian C, Henry S, Shi J, Tetrault J . Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abuse Treat. 2017; 75:49-53. DOI: 10.1016/j.jsat.2016.12.014. View

12.

Christensen S, Buggisch P, Mauss S, Boker K, Schott E, Klinker H . Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction. 2018; 113(5):868-882. DOI: 10.1111/add.14128. View

13.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

14.

Wittchen H, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P . Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend. 2007; 88 Suppl 1:S60-70. DOI: 10.1016/j.drugalcdep.2006.12.013. View

15.

Bawor M, Dennis B, Varenbut M, Daiter J, Marsh D, Plater C . Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015; 6:21. PMC: 4640383. DOI: 10.1186/s13293-015-0038-6. View

16.

Crippa J, Zuardi A, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P . Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009; 24(7):515-23. DOI: 10.1002/hup.1048. View

17.

Bruggmann P, Litwin A . Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013; 57 Suppl 2:S56-61. PMC: 6279207. DOI: 10.1093/cid/cit271. View

18.

Norton B, Fleming J, Bachhuber M, Steinman M, DeLuca J, Cunningham C . High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017; 47:196-201. PMC: 5822435. DOI: 10.1016/j.drugpo.2017.07.021. View

19.

Grebely J, Dore G, Zeuzem S, Aspinall R, Fox R, Han L . Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 2016; 63(11):1479-1481. PMC: 5106608. DOI: 10.1093/cid/ciw579. View